Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ALEC
vs
S&P 500
ALEC
S&P 500
Over the past 12 months, ALEC has underperformed S&P 500, delivering a return of -43% compared to S&P 500's +14% growth.
Stocks Performance
ALEC vs S&P 500
Performance Gap
ALEC vs S&P 500
Performance By Year
ALEC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Alector Inc
Glance View
Alector Inc. is a clinical-stage biotechnology company working on medicines for brain diseases such as Alzheimer’s and frontotemporal dementia. Its idea is to use the body’s immune system, especially cells in the brain called microglia, to help clear harmful proteins and slow disease progression. The company does not sell approved drugs itself; it develops drug candidates and tests them in clinical trials. Alector’s main customers are not patients today but large pharmaceutical partners and, eventually, healthcare systems if its drugs win approval. It makes money mainly through collaboration and license deals with drugmakers, which can include upfront payments, research funding, milestone payments, and future royalties if a partnered drug reaches the market. That means its business depends on advancing a small number of experimental programs rather than selling a broad line of products. What makes Alector different is its focus on immunology inside the brain, which is a less common path in neurodegeneration research. It sits upstream in the drug supply chain as a discovery and development company: it invents candidates, partners when useful, and tries to turn academic biology into medicines. For investors, the key point is that Alector is a research-driven biotech, so its value depends heavily on scientific results, trial progress, and partner support rather than steady product sales.
